JBHT
25
3
R
70
15
RIG
50
3
AKAM
45
2
CLX
53
-2
UHS
63
5
SE
57
7
MUR
52
2
BK
71
2
PRGO
53
3
CHD
66
2
URI
58
9
TXN
42
4
HON
63
3
NEE
50
3
UNH
53
-3
VFC
17
2
JCI
50
3
APH
62
6
NTRS
32
2
JBHT
25
3
R
70
15
RIG
50
3
AKAM
45
2
CLX
53
-2
UHS
63
5
SE
57
7
MUR
52
2
BK
71
2
PRGO
53
3
CHD
66
2
URI
58
9
TXN
42
4
HON
63
3
NEE
50
3
UNH
53
-3
VFC
17
2
JCI
50
3
APH
62
6
NTRS
32
2
Financhill
Back

BioXcel Therapeutics 10K Form

Sell
36

BTAI
BioXcel Therapeutics

Last Price:
2.71
Seasonality Move:
13.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BTAI News And Ratings

See the #1 stock for the next 7 days that we like better than BTAI

BTAI Financial Statistics

Sales & Book Value

Annual Sales: $1.38M
Cash Flow: $-26.86M
Price / Cash Flow: 0
Annual Sales: $-1.89
Price / Book: 0

Profitability

EPS (TTM): -6.14000
Net Income (TTM): $-179.05M
Gross Margin: $120K
Return on Equity: -2323.67%
Return on Assets: -127.86%

BioXcel Therapeutics Earnings Forecast

Key BioXcel Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for BTAI is 8.70%.
  • The Selling, General & Administrative Expenses for BTAI have been equal to 6,044.42% of Gross Profit Margin.
  • The Research & Development expenses have been 6,110.58% of Revenue.
  • The Interest Expense is -7.44% of Operating Income.
  • The Net Earning history of BTAI is -12,974.86% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 0 years.

BioXcel Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BTAI
CUSIP: 09075P
Website: bioxceltherapeutics.com

Debt

Debt-to-Equity Ratio: -1.78
Current Ratio: 2.65
Quick Ratio: 2.39

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BTAI Technical Analysis vs Fundamental Analysis

Sell
36
BioXcel Therapeutics (BTAI) is a Sell

Is BioXcel Therapeutics a Buy or a Sell?